Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Capital Raise

Zai Lab Shares Surge 15% in 10 Days Since Securing $250 Million Via Private Placement

Zai Lab Limited Secures $250 Million via Private Placement for Pipeline Growth

+15.15% in 10 days $22.04 when we broke this story → $25.38 at 12:55 PM ET, 6 Nov 2026

Zai Lab Limited has entered into a securities purchase agreement for a $250 million private placement of 11,340,000 American depositary shares. The transaction, priced at $22.04 per ADS, aims to bolster the company's capital reserves for pipeline advancement and general corporate purposes ahead of its scheduled quarterly financial reporting.

Engineer, engineering, chemical, chemistry. Stock photo illustrating Zai Lab's capital raise story.
Zai Lab Ltd · Healthcare · Photo: This_is_Engineering / Pixabay
Key numbers
Deal value$250M
Share of market cap10.1%

Key highlights

  • Gross proceeds of approximately $250 million from accredited investors in a PIPE transaction
  • Sale of 11,340,000 American depositary shares (ADSs) at $22.04 per share
  • Closing of the private placement scheduled for October 27, 2026
  • Registration statement for the resale of ADSs to be filed within 15 days of closing
  • Capital earmarked for pipeline asset development and working capital requirements

What Is the Capital Raise?

Zai Lab Limited has executed a securities purchase agreement with a group of accredited investors for a private placement of 11,340,000 American depositary shares. Each ADS represents ten ordinary shares of the company, priced at $22.04 per unit. The transaction is structured as a Private Investment in Public Equity (PIPE), which typically allows for efficient capital entry with institutional backing. The closing is expected to occur on or about October 27, 2026, contingent upon standard closing conditions. Following the transaction, Zai Lab has committed to filing a resale registration statement with the SEC to provide liquidity for the newly issued securities.

Use of Proceeds

  • Advancement of the clinical development pipeline for oncology and immunology assets
  • Funding of ongoing and future research and development activities
  • Enhancement of working capital to support operational scaling
  • General corporate purposes to maintain financial flexibility through 2027
  • Strategic support for commercial-stage product stabilization and growth

Financial Context

This $250 million raise follows a pattern of strategic financing for Zai Lab, which previously completed a $200 million underwritten public offering in late 2024. Throughout 2025 and early 2026, the company also established multiple revolving credit facilities with several major banks, totaling over $190 million in available liquidity. This latest infusion of capital arrives just ahead of the company's scheduled third-quarter 2026 financial results on November 5. Management previously projected that operating expenses would remain stable through the end of 2026, with a return to meaningful commercial growth anticipated in the 2027 fiscal year.

Zai Lab Ltd share price · last month
Line chart of Zai Lab Ltd's share price over the last month, from $24.06 on 19 Oct → $23.47 on 16 Nov; our story on 23 Oct at $22.04.

Up 6.5% since our story on 23 Oct: $22.04 when we broke it → $23.47 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$24.06
20 Oct$25.08
21 Oct$24.20
22 Oct$22.04
23 Oct$24.03
26 Oct$24.34
27 Oct$23.58
28 Oct$23.04
29 Oct$22.36
30 Oct$22.07
2 Nov$21.66
3 Nov$21.96
4 Nov$22.80
5 Nov$22.60
6 Nov$25.48
9 Nov$26.86
10 Nov$26.43
11 Nov$26.42
12 Nov$26.04
13 Nov$24.60
16 Nov$23.47

Business Overview

Zai Lab Limited is a commercial-stage biopharmaceutical company focused on bringing transformative medicines to patients in China and globally. The firm specializes in the therapeutic areas of oncology, immunology, and infectious diseases, maintaining operations in both Shanghai and Cambridge, Massachusetts. As an automated intelligence platform notes, the company operates without a traditional order backlog due to the nature of its pharmaceutical sales. Current market technicals show an RSI of 38.1, following a monthly price change of negative 16.55 percent, as the company prepares to transition several key pipeline assets into later-stage clinical milestones.

Earlier announcements by Zai Lab Ltd
DateAnnouncementAmount
22 Oct 2026Private placement (PIPE) of 11,340,000 American Depositary SharesSource: businesswire.com$250.0 Million
25 Feb 2026Working capital revolving credit facility agreement with Bank of CommunicationsSource: SEC filing$41.1 Million
16 Oct 2025Revolving line of credit contract with Industrial BankSource: SEC filing$42.1 Million
06 Aug 2025Working capital credit agreement with China Merchants BankSource: SEC filing$69.6 Million
03 Jan 2025Revolving working capital loan facility agreement with Bank of CommunicationsSource: SEC filing$41.1 Million
14 Nov 2024Underwritten public offering of 7,843,137 American Depositary SharesSource: ir.zailaboratory.com$200.0 Million
Zai Lab Ltd · financial snapshot
Share price$22.04
Market cap$2.5B
Revenue (annual)$460M
1-month price change-16.55%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Zai Lab Limited announcing a $250 million private placement of American depositary shares.

Read the filing ↗

Track Zai Lab Ltd live

Get the next Zai Lab Ltd SEC filing seconds after it lands.

More in Capital Raise

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.